Evidence map›Paper›PMID 35282136›Full record

ArticleAnnals of translational medicine2022

Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study.

Heng Mei, Xiequn Chen, Jianfeng Zhou, Jianmin Luo, Qingzhi Shi, Jing Liu, Depei Wu, Guoan Chen, Yanfei Tai, Junye Xiong and 2 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02614846 (A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02614846 phase1unknown statusnot on this map

A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura

TypeinterventionalSponsorJiangsu HengRui Medicine Co., Ltd.Ran2015Enrolled29ConditionsChronic Idiopathic Thrombocytopenic PurpuraArmsHetrombopag Olamine
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Heng MeiDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiequn ChenHematology Department, The First Affiliated Hospital of Air Force Medical University, Xi'an, China.
Jianfeng ZhouHematology Department, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jianmin LuoHematology Department, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Qingzhi ShiHematology Department, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Jing LiuHematology Department, The Third Xiangya Hospital of Central South University, Changsha, China.
Depei WuHematology Department, The First Affiliated Hospital of Soochow University, Suzhou, China.
Guoan ChenHematology Department, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Yanfei TaiDepartment of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Junye XiongDepartment of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Jianjun ZouDepartment of Clinical Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.
Yu HuDepartment of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jiangsu Hengrui Medicine (China) · CNHuazhong University of Science and Technology · CNNanchang University · CNAir Force Medical University · CNSecond Hospital of Hebei Medical University · CNSoochow University · CNThird Xiangya Hospital · CNTongji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Thrombopoietin receptor agonists (TPO-RAs) are promising therapeutic strategy for patients with immune thrombocytopenia (ITP). We conducted this phase 1 trial (NCT02614846) to evaluate the preliminary efficacy and safety of hetrombopag (a TPO-RA) in patients with ITP. Methods: Patients with ITP who had an insufficient response or had progressed on at least one standard treatment for ITP were given hetrombopag orally at an initial dose of 5 mg once daily for up to 6 weeks. The primary endpoint was the proportion of patients who achieved platelet counts of ≥50×10 Results: A total of 37 eligible patients received hetrombopag treatment. This study met its primary endpoint, 22 (59.5%, 95% CI: 42.1-75.3) patients responded to hetrombopag, achieving platelet counts ≥50×10 Conclusions: Hetrombopag showed preliminary activity in elevating platelet counts and reducing bleeding in patients with chronic ITP who had received at least one standard therapy. It was well-tolerated.

Indexed as

clinical trialhematologic responseHetrombopagimmune thrombocytopenia (ITP)thrombopoietin receptor

Identifiers

PMID35282136
PMCPMC8848441
OpenAlexW4205264472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.